In this paper, we demonstrate that ANG2-functionalised hexavalent TRAIL receptor agonists retain their potency in killing GBM cells, that BBB endothelial cells are resistant to TRAIL and able to transport large ANG2-based fusion proteins across the BBB. Here, TNFSF10 is linked to glioblastoma.